Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cell Lines01:16

Cell Lines

8.3K
A cell line is a population of cells grown in vitro that can be subcultured over several generations. Normal cells cease to divide after a certain number of cell divisions, a process known as replicative senescence. This number, called the Hayflick limit, was conceptualized by Leonard Hayflick in 1961 when he observed that fetal cells grown in culture could only divide 40-60 times. This limit is due to the shortening of the telomeres during each round of cell division, preventing cell division...
8.3K
Upstream Processing01:27

Upstream Processing

97
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
97
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

94
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
94

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized Study of Intravitreal Autologous CD34+ Stem Cells in Central Retinal Vein Occlusion (Treatment of Retinal vein occlusion Using STem cells [TRUST] Report 1): Safety and Feasibility.

Ophthalmology science·2026
Same author

Intravitreal Transplantation of Retinal Progenitor Cells Improves Outcome Measures in a Rat Model of Diabetic Retinopathy.

International journal of molecular sciences·2025
Same author

Retinal progenitor cells (jCell) for retinitis pigmentosa.

Frontiers in cellular neuroscience·2025
Same author

Retraction Note: Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cells.

Nature communications·2025
Same author

GMP manufacturing of cell and gene therapy products: Challenges, opportunities, and pathways forward.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Hand and Forearm Compartment Syndrome Secondary to Intravenous Infiltration.

Journal of orthopaedic case reports·2024
Same journal

Erratum.

Developments in ophthalmology·2021
Same journal

Pediatric Vitreoretinal Surgery and Integrated Intraoperative Optical Coherence Tomography.

Developments in ophthalmology·2021
Same journal

Integrated Intraoperative Optical Coherence Tomography for Pediatric Lamellar Corneal Transplant Surgery.

Developments in ophthalmology·2021
Same journal

The Use of Optical Coherence Tomography as an Intraoperative Adjunct of Oculoplastic Surgery.

Developments in ophthalmology·2021
Same journal

Integrated Intraoperative Optical Coherence Tomography in Strabismus Surgery.

Developments in ophthalmology·2021
Same journal

Use of Integrated Intraoperative Ocular Coherence Tomography in Pediatric Cataract Surgery: Thinking outside the Box.

Developments in ophthalmology·2021
See all related articles

Related Experiment Video

Updated: May 1, 2026

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow
09:03

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow

Published on: March 17, 2023

4.1K

Cellular manufacturing for clinical applications.

Jonathan Sheu1, Henry Klassen, Gerhard Bauer

  • 1Institute for Regenerative Cures, University of California Davis School of Medicine, Sacramento, Calif., USA.

Developments in Ophthalmology
|April 16, 2014
PubMed
Summary
This summary is machine-generated.

Manufacturing clinical-grade cell therapies for retinal diseases requires strict Good Manufacturing Practice (GMP) standards. Novel bioreactor systems offer scalable solutions for large-dose production, advancing therapeutic development.

More Related Videos

Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers
09:44

Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers

Published on: July 7, 2023

5.0K
Automated Counterflow Centrifugal System for Small-Scale Cell Processing
04:49

Automated Counterflow Centrifugal System for Small-Scale Cell Processing

Published on: December 12, 2019

8.6K

Related Experiment Videos

Last Updated: May 1, 2026

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow
09:03

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow

Published on: March 17, 2023

4.1K
Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers
09:44

Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers

Published on: July 7, 2023

5.0K
Automated Counterflow Centrifugal System for Small-Scale Cell Processing
04:49

Automated Counterflow Centrifugal System for Small-Scale Cell Processing

Published on: December 12, 2019

8.6K

Area of Science:

  • Regenerative Medicine
  • Ophthalmology
  • Biotechnology

Background:

  • Cell-based therapies show promise for retinal degenerative diseases.
  • Clinical translation requires adherence to stringent manufacturing standards.
  • Good Manufacturing Practice (GMP) is essential for regulatory approval.

Purpose of the Study:

  • To outline GMP principles for manufacturing clinical-grade cellular products.
  • To explore scalable methods for cell expansion and processing.
  • To compare conventional and novel manufacturing systems for cell therapeutics.

Main Methods:

  • Review of GMP standards for personnel, materials, procedures, and facilities.
  • Discussion of scale-up strategies for large-dose cell therapy production.
  • Comparison of traditional culture methods (flasks, cell factories) with novel bioreactors (hollow-fiber).

Main Results:

  • GMP compliance is critical for the clinical use and approval of cell-based therapeutics.
  • Novel bioreactor systems, like hollow-fiber systems, offer advantages for large-scale cell manufacturing.
  • These advanced systems can provide sufficient cell numbers for multi-center trials.

Conclusions:

  • Implementing novel bioreactor systems within GMP facilities is key to meeting the demand for cell therapies.
  • This approach facilitates the development of effective treatments for a large patient population with retinal diseases.
  • Scalable GMP manufacturing is crucial for the future of cell-based ophthalmology therapeutics.